Anticoagulation in permanent atrial fibrillation after 75 years

被引:4
作者
Tilly-Gentric, A [1 ]
机构
[1] CHU La Cavale Blanche, Serv Med Interne 2, F-29200 Brest, France
来源
REVUE DE MEDECINE INTERNE | 2002年 / 23卷 / 10期
关键词
elderly; permanent atrial fibrillation; ischemic stroke; primary and secondary prevention; under utilisation of oral anticoagulants;
D O I
10.1016/S0248-8663(02)00691-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose. - More than 10% of the population over 75 years old is concerned by non valvular permanent atrial fibrillation which is responsible for at least 30% of ischemic strokes. The indication of an anticoagulant therapy is discussed in two different situations: primary or secondary prevention of stroke and acute phase of stroke. Current knowledge and key points. - Patients over 75 years old have a high risk of stroke (> 8% year). All the studies have demonstrated the benefit of a primary or secondary prevention by antivitamin K with an INR between 2 and 3 (reduction of the relative risk of about 68%). Conversely, the efficacy of aspirin has not been proven in this population of elderly patients. Once stroke has occurred, it is not recommended to initiate an anticoagulation (unfractioned or low molecular weight heparin) within the first hours. Prevention of venous thrombosis remains necessary. Future prospects and projects. - Currently, less than 30% of the patients older than 75 years are given anticoagulation, the risk of the treatment being probably overestimated. The risk benefit ratio should be evaluated more properly for a given patient. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
引用
收藏
页码:834 / 839
页数:6
相关论文
共 38 条
[1]  
ABALGOTTA M, 1998, J AM COLL CARDIOL, V31, P1622
[2]  
[Anonymous], 2001, CIRCULATION, V104, P2118
[3]   Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients [J].
Aronow, WS ;
Ahn, C ;
Gutstein, H .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1996, 44 (05) :521-523
[4]  
BEGE E, 2000, LANCET, V355, P1205
[5]  
Blackshear JL, 1996, LANCET, V348, P633
[6]  
*BOST AR ANT TRIAL, 1992, NEW ENGL J MED, V323, P1505
[7]   Cardioversion of atrial fibrillation in the elderly [J].
Carlsson, J ;
Tebbe, U ;
Rox, J ;
Harmjanz, D ;
Haerten, K ;
Neuhaus, KL ;
Seidel, F ;
Niederer, W ;
Miketic, S .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (12) :1380-1384
[8]  
Chesebro JH, 1996, ARCH INTERN MED, V156, P409
[9]   HOW DO PHYSICIANS WEIGH IATROGENIC COMPLICATIONS [J].
COHEN, BJ ;
PAUKER, SG .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1994, 9 (01) :20-23
[10]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355